LYEL Lyell Immunopharma, Inc.: Projected Price to Earnings

LYEL (Lyell Immunopharma) - company brandmark

Lyell Immunopharma (LYEL) is a biotech startup whose financial model relies on external funding due to the lack of stable earnings during the development phase. This price chart demonstrates a separate_f_pe metric of 0.00. The company's success depends on the outcomes of primary trials for anti-tumor drugs, while existing liquid assets are sufficient to cover current operating expenses.

lyell.com - LYEL Future Price to Earnings Multiple (period 07/04/2022 - 11/18/2026)

Metric breakdowns and analytics for lyell.com (LYEL)

- stock quotes and analyst forecast:
- company stock capitalization data:
Fundamental company analysis:Lyell LYEL
Signature product of Lyell Immunopharma

The assessment of the asset's margin of safety is based on comparing the current price with projected earnings. The innovative T-cell reprogramming ecosystem of Lyell Immunopharma (LYEL) lays the foundation for radical growth in future revenues. The company's forward P/E ratio reflects market expectations regarding the efficacy of this solid tumor therapy. This metric measures the cost of one dollar of expected profit, revealing whether the business is overvalued or undervalued. This tool characterizes the asset as a high-risk venture object.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Arcus Biosciences (RCUS) - Projected Price to Earnings Ratio|ZYME: Projected Price to Earnings|Future Price to Earnings Multiple TNGX (Tango Therapeutics, Inc.)|IOVA: Forward P/E Multiple|IMTX - Market Cap to Projected Earnings|Future Price to Earnings xencor.com|Projected Price to Earnings compasstherapeutics.com (CMPX)|Future Price to Earnings Replimune Group Inc (REPL)|Projected Price to Earnings Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Projected Price to Earnings|Forward P/E Multiple Compugen Ltd. CGEN|IOBT - Future Price to Earnings|STRO (sutrobio.com) - Price to Future Earnings Ratio|MiNK Therapeutics, Inc (INKT) - Future Price to Earnings|Projected Price to Earnings Ratio Werewolf Therapeutics (HOWL)|Projected Price to Earnings IMMX|ALXO - Forward Price to Earnings Multiple|Forward P/E Multiple CUE|Market Cap to Future Earnings Ratio PDSB|Forward P/E Multiple SONN (Sonnet BioTherapeutics)|Future Price to Earnings Multiple MAIA|liminatuspharma.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple